Advesya

En visite à Dijon, le ministre délégué chargé de l'Industrie, Marc Ferracci, a salué « une filière santé qui a un véritable ancrage territorial ». Plus d'informations sur https://lnkd.in/eVyWeE9w #innovation #santé #industries #pharma #biotech #medtech #healthtech Advesya Christophe FERRAND Marina DESCHAMPS Archeon Medical Alban De Luca Pierre-Edouard Saillard EKTAH Naim Khan Xavier Boidevézi Inventiva Pharma Frederic Cren Jean VOLATIER Pierre Broqua ASTREA FONTAINE PROTEOR Santenov Danielle JUBAN Préfecture de la région Bourgogne-Franche-Comté, préfecture de la Côte d’Or Jean-Pierre Yalcin

A big "Merci" to the organizers of Innovative Therapies Days for the opportunity to present our research! 🔬 Advesya's CMO Jens H. had a great time sharing our science and route from the bench to the clinic for #CCTx001. And also congratulations to our fantastic scientists Lucie Bouquet and Soha El Sayed for presenting our science posters on #CCTx001 and #ADV101 👏 #Biotech #Research #Collaboration #Advesya #regionbourgognefranchecomte

🎧 Écoutez Christophe FERRAND, co-fondateur d'Advesya discuter de l'histoire et de l'état des recherches sur les CAR-T ! 🚀🔬 #CellTherapy #Biotech #Immunotherapy #Innovation #HealthcareTech

Just a reminder that our CEO Ksenija Pavletic and our CSO Richard C. A. Sainson will be attending the upcoming ESMO conference starting next week on September 13th Our colleagues will be there to discuss our innovative approach to targeting IL1RAP using our cell therapy, #CCTx001, and our ADCs, #ADV101, which are currently being developed for the treatment of AML and solid tumors. If you're attending, they’d love to connect—reach out and learn more! 🌍🤝 #ESMO2024 #ADCs #SolidTumors #Oncology #Innovation #Collaboration #CellTherapy #Networking #AML #ADV101 #CCTx001

🌍🔬 Today is World Leukemia Day—a day to raise awareness and show support for everyone affected by leukemia. At Advesya, we are deeply committed to advancing the fight against leukemia. Our team is dedicated to developing innovative solutions and provide new life-saving treatments to patients across the globe. Let’s come together today to raise awareness and continue pushing forward in the mission to find a cure. 🎗️ 💛 🩸 #WorldLeukemiaDay #FightLeukemia #InnovateForLife #ResearchForACure #CCTx001 #ADV101 #AML

🔬 Really interesting to read about this new study on targeting IL-1RAP in AML! IL-1RAP is highly expressed on AML blasts and leukemic stem cells but not on healthy Hematopoietic stem cells, making it an ideal target for selective cancer therapy. This research introduces a T-cell engager that specifically targets IL-1RAP on AML cells and LSCs, showing great promise in eliminating the disease with minimal impact on healthy cells. Targeting IL-1RAP could revolutionize AML treatment, especially for patients with relapsed or refractory disease, by addressing the root of the disease and preventing recurrence. #AML #CancerResearch #Immunotherapy #HealthcareInnovation #CCTx001 #ADV101 Link: DOI:10.1186/s13045-024-01586-x

🌍 Excited to represent Advesya at #ESMO24 next month and have the opportunity to attend presentations and posters, and meet with potential collaborators. We would love to connect, so feel free to reach out! 🤝 🇪🇸 #ESMO2024 #Networking #CCTx001 #ADV101 #Oncology #IL1RAP #CellTherapy #AML #ADC

🚀 We are very pleased to share that our portfolio company Advesya has received approval from the European Medicines Agency (EMA) to initiate the phase 1/2 trial of its lead asset, CCTx-001, to address the medical needs of patients with acute myeloid leukemia (AML).   AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment   The #RESOLVE AML 001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML.   #biopharma #innovation #hematology #oncology #clinicalstudy

🚀 We are delighted to announce that Advesya has received approval from the EMA to start the phase 1/2 trial of our investigational lead asset, CCTx-001, to address the unmet medical needs of patients with relapse and refractory acute myeloid leukemia (AML).   The RESOLVE-AML-001 study will determine the recommended phase 2 dose of CCTx-001 and will assess safety, tolerability, and clinical activity in patients with relapsed/refractory AML. AML is a cancer of the bone marrow and the blood that progresses rapidly without treatment.Advesya is committed to accelerating the development of innovative cancer treatments for patients suffering from this hard-to-treat hematological cancer and who currently have no treatment options. Learn more 👉 www.advesya.com #ClinicalTrials #CellTherapy #Hematology #CancerResearch #AML #InnovativeTherapies #PatientCare #Healthcare #Biotech #CCTx001